<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="850">
  <stage>Registered</stage>
  <submitdate>14/09/2005</submitdate>
  <approvaldate>14/09/2005</approvaldate>
  <nctid>NCT00202280</nctid>
  <trial_identification>
    <studytitle>Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication</studytitle>
    <scientifictitle>VIP (Vitamins In Psychosis) Study. A Randomized Double Blind Placebo Controlled Trial of the Effects of Vitamin B12, B6 and Folic Acid Augmentation on Cognition and Symptoms in Early Psychosis.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>03T-472</secondaryid>
    <secondaryid>BPREC 26/2004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>First Episode Psychosis</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Psychosis and personality disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg

Placebo Comparator: Placebo pill - Placebo pill daily for 3 months

Experimental: 5mg folic acid, 0.4mg B12, 50mg B6 - 5mg folic acid, 0.4mg B12, 50mg B6 in one pill, daily for 3 months


Treatment: drugs: Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cognition (MATRICS and COGSTATE)at 3 months</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Symptomatology at 3 months</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety at 3 months</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability at 3 months</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male and females

          -  Between 15 and 25 years of age

          -  First Episode Psychosis

          -  3 months of treatment

          -  Attending ORYGEN Youth Health, a geographical based catchment area service for young
             people aged between 15 and 25</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>25</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Untreated B12 deficiency or untreated pernicious anaemia

          -  Patients on multi-vitamins, single B6, or folic acid, unless willing to discontinue
             and take study supplement

          -  Chronic haemolytic states such as thalassaemia major or sickle-cell anaemia

          -  Hypersensitivity to folic acid

          -  Organic disorders presenting with a psychotic syndrome (e.g. brain tumour, temporal
             lobe epilepsy, HIV encephalopathy)

          -  Mental retardation (unable and/or unlikely to give appropriate information of
             symptomatology or side-effects (IQ approximately lower than 70)

          -  History of clinically significant physical illness (e.g. terminal cancer, renal
             dialysis)

          -  History of brain surgery

          -  History of brain infarction

          -  Pregnant or lactating women, or women of childbearing potential not using an
             acceptable method of contraception</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>120</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>ORYGEN Youth Health - Melbourne</hospital>
    <postcode>3052 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Stanley Medical Research Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether Vitamin B12,B6 and Folic Acid are effective
      with antipsychotic medication in the treatment of First Episode Psychosis.The B-complex
      Vitamins' homocysteine lowering properties may have an effect on cognition and symptoms. We
      are examining changes in symptoms and cognition over a 3 month period.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00202280</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Colin P O'Donnell, MB,MRCPsych</name>
      <address>ORYGEN Research Centre , ORYGEN Youth Health,Department of Psychiatry, University of Melbourne</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>